Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00552305 · ClinicalTrials.gov registry record · Phase 2
To Determine Tolerability and Efficacy of Long-term Oral Lacosamide in Patients With Partial Seizures
A Phase 2 study of Partial Epilepsies, sponsored by UCB Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 370
- Enrollment target
- 20
- Study locations
NCT00552305 is a Phase 2 study of Partial Epilepsies that has completed, run by UCB Pharma. The registered enrollment target is 370 participants. The trial reports 20 study locations across 12 states.
The verdict
NCT00552305, a Phase 2 study of Partial Epilepsies, has completed, sponsored by UCB Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 370 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this trial is to determine whether lacosamide is safe and effective for long-term use in patients with partial-seizures from epilepsy.
Conditions Studied
Interventions
- DRUG lacosamide
Study Locations (20)
Florida
- - Gainesville
- - Hollywood
- - Miami
- - Ponte Vedra Beach
Alabama
- - Birmingham
- - Huntsville
Arizona
- - Phoenix
- - Tucson
Illinois
- - Chicago
- - Springfield
Kentucky
- - Crestview Hills
- - Lexington
Maryland
- - Baltimore
- - Frederick
Arkansas
- - Little Rock
California
- - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 370 participants |
| Start Date | 2001-08 |
| Est. Completion | 2010-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00552305
The ClinicalTrials.gov registry entry for NCT00552305 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 370 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Pharma, which has 100 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Partial Epilepsies appearing as the primary indexed condition, and to 1 intervention - of which lacosamide is the first listed.
NCT00552305 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Florida, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT00552305 about?
NCT00552305 is a clinical study titled "To Determine Tolerability and Efficacy of Long-term Oral Lacosamide in Patients With Partial Seizures". The purpose of this trial is to determine whether lacosamide is safe and effective for long-term use in patients with partial-seizures from epilepsy.
What is the current status of trial NCT00552305?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 370 participants. The study started on 2001-08. Estimated completion is 2010-02.
What conditions does trial NCT00552305 study?
This clinical trial studies the following conditions: Partial Epilepsies.
What interventions are being tested in trial NCT00552305?
The interventions under investigation include: lacosamide (DRUG).
Who is sponsoring clinical trial NCT00552305?
This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00552305 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Partial Epilepsies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.